Loading...
XNYS
PEN
Market cap11bUSD
Dec 05, Last price  
300.66USD
1D
2.02%
1Q
6.82%
Jan 2017
371.25%
IPO
651.65%
Name

Penumbra Inc

Chart & Performance

D1W1MN
XNYS:PEN chart
P/E
840.31
P/S
9.86
EPS
0.36
Div Yield, %
Shrs. gr., 5y
1.60%
Rev. gr., 5y
16.89%
Revenues
1.19b
+12.86%
73,141,00088,848,000125,510,000186,095,000263,317,000333,764,000444,938,000547,405,000560,412,000747,590,000847,133,0001,058,522,0001,194,615,000
Net income
14m
-84.59%
1,958,0004,099,0002,245,0002,365,00014,814,0004,657,0006,601,00048,458,000-19,257,0002,623,000-2,002,00090,954,00014,012,000
CFO
168m
+73.10%
-3,396,000-6,389,000-22,279,000-12,807,00012,691,00028,808,00026,652,000-33,242,0009,502,000-55,661,00097,333,000168,481,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
IPO date
Sep 18, 2015
Employees
3,900
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT